



MEDICAL DEVICES



PHARMACEUTICALS



CHEMICALS



FOOD & BEVERAGE



ELECTRONICS

## ***Table of Contents and List of Tables***

Copyright 2012 VENTURE PLANNING GROUP  
This material is confidential for use by our clients only  
and may not be reprinted or reproduced.

VPG Publications, Consulting, Clients [www.VPGcorp.com](http://www.VPGcorp.com)

VPG Market Research Reports [www.VPGMarketResearch.com](http://www.VPGMarketResearch.com)

VPG Partner Reports [www.Research-Store.com/VPG](http://www.Research-Store.com/VPG)

**VENTURE PLANNING GROUP** 545 Eighth Avenue, Suite 401 New York, NY 10018  
Phone + 1 212 564 2838 Fax + 1 212 564 8133 [info@vpgcorp.com](mailto:info@vpgcorp.com)

## Table of Contents

### Introduction

### Worldwide Market And Technology Overview

#### A. DNA Sequencing

1. Introduction
2. Sequencing Methods
3. Autoradiography
4. The Human Genome Project
5. Sequencing Automation
6. Image Scanners
7. Fluorescent Detection
8. Gene Profiling
9. Gene Expression
10. Polymorphism Screening
11. Protein Interaction Networks

#### B. DNA And RNA Probe Technology

1. Basic Principles
2. Probe Preparation
3. The DNA Probe Test
  - a. Sample Preparation
  - b. Hybridization
  - c. Separation
  - d. Detection/Measurement
4. Test Formats
  - a. Filter Hybridization
  - b. Southern Blot
  - c. Northern Blot
  - d. In Situ Hybridization
  - e. Others
5. Labeling Techniques
6. Amplification Methods
  - o Polymerase Chain Reaction
    - Temperature Cyclers

Table of Contents (continued)

- PCR Variations
    - \* Immuno-PCR
    - \* QC-PCR
    - \* DAP-PCR
  - o Strand Displacement Activation
  - o TMA
  - o Ligase Chain Reaction
  - o Branched DNA
    - Hybridization Protection Assay
  - o Nucleic-Acid Sequence-Based Amplification
  - o Self-Sustained Sequence Replicase
  - o Others
    - Ampliprobe
    - CAR
    - CAS
    - CPT
    - Dendritic Polymer Technology
    - ISO-CR
    - LAT
    - Probe Networks
    - RAMP
    - Repair Chain Reaction
    - Rolling Circles
    - Sequence Independent Gene Amplification
    - Sequence Initiation Reaction
    - SISPA
    - Solid Phase Amplification
- C. Detection Technologies
1. Radioactive Methods
    - a. Overview
    - b. Major Isotopes
      - o P-32
      - o S-35
      - o H-3
      - o I-125
  2. Non-Isotopic Methods
    - a. Enzymatic Labels
    - b. Chemical Labeling
      - o Indirect Chemical Labeling
      - o Direct Chemical Labeling

Table of Contents (continued)

- c. Fluorescence
- d. Chemiluminescence
- e. Electrical Conductivity
- D. Instrumentation Review
  - 1. Abbott LCx
  - 2. Beckman Coulter/Biomek FK
  - 3. Becton Dickinson SDA
  - 4. Bio-Rad GeneScope
  - 5. Gen-Probe Tigris
  - 6. Roche Cobas AmpliCor
  - 7. Tecan LS Series
- E. Biochips: Genosensors, Microarrays, and Labs-on-the-Chip
  - Liquid Transportation and Mixing
  - Separation
  - Reaction
  - Detection
- F. Pharmacogenomics
- G. Major Applications
  - 1. Microbiology/Infectious Diseases
    - a. Overview
    - b. Major Infectious Diseases
      - \* AIDS
        - o Structure and Composition
        - o Classification
        - o AIDS Origins
        - o Animal Lentivirus Systems
        - o Virus Receptors
        - o HIV Infections in Humans
          - Pathogenesis and Pathology
        - o CD4T Lymphocytes and Memory Cells
        - o Monocytes and Macrophages
        - o Lymphoid Organs
        - o Neural Cells
        - o Viral Coinfections
          - Clinical Findings
        - o Plasma Viral Load

Table of Contents (continued)

- *Pediatric AIDS*
  - *Neurologic Disease*
  - *Opportunistic Infections*
  - *Cancer*
- *Immunity*
  - *Virus Isolation*
  - *Serology*
  - *Viral Nucleic Acid/Antigen Detection*
- *Epidemiology*
  - *Worldwide Spread of AIDS*
  - *United States*
  - *Routes of Transmission*
- *DNA Probes*
  - *Overview*
  - *Quantitative PCR*
  - *In Situ PCR*
  - *Needed Improvements*
- *Viral Load/Drug Resistance Testing*
- *Genotype and Phenotype Testing*
- *Blood Banking Considerations*
- \* *Adenovirus*
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
  - *Adeno-Associated Viruses (AAV)*
- \* *Anthrax/Bacillus Anthracis*
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* *Babesiosis*
  - *Background*
- \* *BEA and Other Bartonella Diseases*
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* *Chagas Disease*
  - *Background*

Table of Contents (continued)

- \* *Campylobacter*
  - *Background*
  - *Diagnostic Tests*
    - *Culture Identification*
  - *Vaccines and Drugs*
- \* *Chlamydia*
  - *Background*
    - *Chlamydia psittaci*
    - *Chlmaydia pneumoniae*
    - *Chlamydia trachomatis*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* *Creutzfeldt-Jakob's Disease*
  - *Background*
  - *Blood Transmission*
  - *Diagnostic Tests*
  - *Major Commercial and Academic Players*
    - *Bayer*
    - *Disease Sciences/Bio Tec Global*
    - *Imperial College School of Medicine*
    - *Ortho-Clinical Diagnostics*
    - *Pall*
    - *ProMetic Life Sciences*
    - *Proteome Sciences/Idexx*
    - *Q-One Biotech*
    - *Serono*
    - *U.S. Agricultural Research Service*
  - *Drugs*
  - *Vaccines*
- \* *Cytomegalovirus*
  - *Background*
    - *Chorioretinitis*
    - *Gastrointestinal*
    - *Central Nervous System Disease*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* *Ebola Virus*
  - *Background*
    - *Epidemiology*
    - *Clinical Syndromes*

Table of Contents (continued)

- *Diagnostic Tests*
- *Vaccines and Drugs*
- \* *EchoVirus*
  - *Background*
    - *Acute Aseptic Meningitis*
    - *Encephalitis*
    - *Exanthems*
    - *Respiratory Disease*
    - *Myopericarditis*
    - *Neonatal Infections*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* *Encephalitis*
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* *Enteroviruses*
  - *Background*
  - *Diagnostic Tests*
    - *Viral Isolation and Identification*
    - *Antibody Tests*
  - *Vaccines and Drugs*
- \* *Epstein-Barr Virus*
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* *Gonorrhoea*
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* *Hepatitis*
  - *Hepatitis A*
  - *Hepatitis B*
    - *Structure and Composition*
    - *Replication*
  - *Hepatitis C*
  - *Hepatitis D (Delta)*
  - *Hepatitis E*
  - *Hepatitis G*
  - *Hepatitis Infections Pathology*
  - *Clinical Findings*
  - *Laboratory Tests*

Table of Contents (continued)

- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
- o Virus-Host Immune Reactions
- o Epidemiology
  - Hepatitis A
  - Hepatitis B
  - Hepatitis C
  - Hepatitis D (Delta)
- o Vaccines and Drugs
- \* Herpes Simplex Virus
  - o Background
  - o Diagnostic Tests
  - o Vaccines and Drugs
- \* Legionella
  - o Background
  - o Diagnostic Tests
  - o Vaccines and Drugs
- \* Lyme Disease
  - o Background
    - Clinical Description
    - Clinical Case Definition
    - Laboratory Criteria for Diagnosis
    - Case Classification
  - o Diagnostic Tests
  - o Vaccines and Drugs
- \* Malaria
- \* Mycoplasma
  - o Background
    - Ureaplasma Urealyticum & Mycoplasma Hominis
  - o Diagnostic Tests
  - o Vaccines and Drugs
- \* Papillomaviruses/HPV
  - o Background
    - HPV in Cancer
    - Cervical Neoplasm
  - o Diagnostic Tests
  - o Vaccines and Drugs



Table of Contents (continued)

- Prevention
- \* **Parvovirus B19**
  - o Background
    - Microbiology
    - Epidemiology
    - Clinical Syndromes
    - Erythema Infectiosum (Slapped Cheek)
    - Adult Polyarthropathy
    - Transient Aplastic Crisis
    - Transient Pancytopenia
    - Red Cell Aplasia in Immunocompromised
    - Perinatal Infections
  - o Diagnostic Test
  - o Vaccines and Drugs
- \* **Pneumonia**
  - o Background
  - o Diagnostic Tests
  - o Vaccines and Drugs
- \* **Polyomaviruses**
  - o Background
  - o Diagnostic Tests
  - o Vaccines and Drugs
- \* **Salmonellosis**
  - o Background
  - o Diagnostic Tests
  - o Vaccines and Drugs
- \* **Shigellosis**
  - o Background
  - o Diagnostic Tests
  - o Vaccines and Drugs
- \* **Streptococci**
  - o Background
  - o Diagnostic Tests
  - o Vaccines and Drugs
    - Group A Streptococci
    - Group B Streptococci
- \* **Toxoplasmosis**
  - o Background
  - o Diagnostic Tests
  - o Vaccines and Drugs

Table of Contents (continued)

- \* **Tuberculosis**
    - **Background**
    - **Diagnostic Tests**
      - **Microscopic Characteristics**
      - **Cultural Characteristics**
      - **Skin Tests**
      - **MDRTB**
    - **Vaccines and Drugs**
  - \* **West Nile Virus**
    - **Background**
      - **Clinical Syndromes**
    - **Diagnostic Tests**
    - **Vaccines and Drugs**
  - \* **Yersinia**
    - **Background**
    - **Diagnostic Tests**
    - **Vaccines and Drugs**
  - c. **Antibiotic Susceptibility**
- 2. Cancer Testing**
- a. **Overview**
  - b. **Major Cancer Types**
    - \* **Prostate**
    - \* **Lung**
    - \* **Colon and Rectum**
    - \* **Breast**
    - \* **Skin**
    - \* **Uterine**
    - \* **Leukemia**
    - \* **Oral**
  - c. **Oncogenes**
    - **Abl/abl-bcr**
    - **AIB1**
    - **BCL-2**
    - **BRCA1**
    - **CD44**
    - **C-fos**
    - **C-myb**
    - **C-myc**
    - **CYP17**
    - **Erb-B**
    - **HPC1**

Table of Contents (continued)

- *N-myc*
- *P40*
- *P51*
- *P53*
- *PIK3CA*
- *PTI-1*
- *Ras*
- *Reg*
- *Sis*
- *Src*
- 3. *Genetic Diseases*
  - a. *Overview*
  - b. *Nucleic Acid Amplification*
  - c. *Chromosome Imaging*
  - d. *Genomics Technologies*
  - e. *Proteomics Technologies*
  - f. *Current Pharmacogenomic Tests*
  - g. *Future Pharmacogenomic Testing*
  - h. *Major Diseases*
    - \* *Achondroplasia*
    - \* *Autosomal Dominant Polycystic Kidney Disease*
    - \* *Cancer*
    - \* *Cosmetogenomics*
    - \* *Cystic Fibrosis*
    - \* *Down's Syndrome*
    - \* *Duchenne and Becker Muscular Dystrophy*
      - \* *Factor V (Leiden)*
      - \* *Factor IX Deficiency*
      - \* *Fragile X Syndrome*
      - \* *Heart Disease*
      - \* *Hemochromatosis*
      - \* *Hemophilia*
      - \* *Huntington's Disease*
      - \* *Maternal-Fetal Incompatibility*
      - \* *Multiple Endocrine Neoplasia*
      - \* *Phenylketonuria (PKU)*
      - \* *Polycystic Kidney Disease (PKD)*
      - \* *Prenatal Screening*
      - \* *Retinitis Pigmentosa*
      - \* *Retinoblastoma*
      - \* *Sickle Cell Anemia*

Table of Contents (continued)

- \* Spinal Muscular Atrophy
- \* Vitamin B12 Metabolism
- i. Social Issues and Concerns
- 4. Forensic Testing
  - a. Overview
  - b. Multilocus and Single Locus Probes
    - \* Multilocus Probes
    - \* Single Locus Probes
    - \* PCR and RFLP
  - c. The FBI
  - d. DNA Profile Data Banks
    - \* U.S.A.
    - \* U.K.
  - e. Judicial Implementation
  - f. Major Crime Categories
  - g. Factors Contributing to the DNA Probe Market Expansion
    - \* Technology Availability
    - \* Use of Hair as Evidence
  - h. Wildlife Forensics
- 5. Paternity Testing/HLA Typing
- 6. Other Applications
  - a. Disease Susceptibility Testing
  - b. Cardiovascular Diseases
  - c. Diabetes
  - d. Alzheimer's Disease
  - e. Periodontal Disease
  - f. Plasma Purification
  - g. Organ Transplantation
  - h. Water Contamination
  - i. Other
- H. Competing/complementing Technologies
  - 1. Monoclonal Antibodies/Immunoassays
  - 2. RNA Probes
  - 3. Two-Dimensional Electrophoresis
  - 4. Flow Cytometry
- I. Worldwide Market Overview
  - 1. Business Environment
  - 2. Market Structure
  - 3. Market Size and Growth

Table of Contents (continued)

USA

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth And Major Suppliers' Sales And Market Shares

Major Product Development Opportunities

- A. Instrumentation
- B. Reagent Kits and Test Systems/panels
- C. Computers, Software and Automation
- D. Auxiliary Products

Design Criteria For Decentralized Testing Products

Alternative Market Penetration Strategies

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies For Decentralized Testing Markets
  - 1. Marketing Approaches
  - 2. Product Complexity
  - 3. Customer Preference
  - 4. Established Suppliers
  - 5. Emerging Suppliers
  - 6. Major Types Of Distributors
  - 7. Market Segmentation

Potential Market Entry Barriers And Risks

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge And Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

Table of Contents (continued)

Competitive Profiles

- Abbott
- Affymetrix
- Agilent
- Applied Gene Technologies
- Arca
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- BioMerieux
- Bio-Rad
- Biotest
- Caliper
- Cepheid
- Decode
- Diadexus
- Eiken
- Enzo
- Exact Sciences
- Fujirebio
- Gen-Probe
- Hologic
- Illumina
- Innogenetics/Solvay
- Kreatech
- Li-Cor Biosciences
- Life Technologies
- Monogram Biosciences
- Myriad Genetics
- Nanogen/Elitech
- Novartis
- Orchid CellMark
- Ortho-Clinical Diagnostics
- Proteome Sciences
- Qiagen
- Roche
- Scienion
- Sequenom
- Shimadzu
- Siemens
- Sierra Molecular
- Takara Bio
- Tecan Group

Table of Contents (continued)

Appendixes

*Appendix I: Major Universities and Research Centers  
Developing NAT Technology*

*Appendix II: Glossary of Terms*

*Appendix III: Currency Exchange Rates*

List of Tables

*Major Companies Developing or Marketing AIDS NAT  
And Other Direct Identification Tests*

*Major Companies Developing or Marketing Adenovirus  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Campylobacter  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Chlamydia  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing CMV Molecular  
Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing EBV Molecular  
Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Gonorrhea  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Hepatitis  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Herpes  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Legionella  
NAT And Other Direct Identification Tests*



List of Tables (continued)

*Major Companies Developing or Marketing Lyme  
Disease NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Mycoplasma  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Papilloma  
Virus NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Pneumonia  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Salmonella  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Shigella  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Streptococci  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Toxoplasmosis  
NAT And Other Direct Identification Tests*

*Major Companies Developing or Marketing Tuberculosis  
NAT And Other Direct Identification Tests*

*Oncogenes Potential Application in Cancer Diagnosis*

*Major Companies Developing or Marketing Cancer  
NAT Tests*

List of Tables (continued)

*Major Companies Developing or Marketing NAT Assays  
For Genetic Diseases*

*Summary Table U.S.A., NAT Test Volume  
And Sales Forecast by Major Application*

*U.S.A., Laboratories Performing  
DNA Sequencing by Market Segment*

*U.S.A., NAT Market, Potential  
Laboratory Universe by Market Segment*

*U.S.A., NAT Test Volume Forecast By Major Application*

*U.S.A., Major Infectious Disease NAT Test Volume Forecast*

*U.S.A., Infectious Disease Screening  
NAT Volume by Test Forecast*

*U.S.A., NAT Market Forecast By Major Application*

*U.S.A., Infectious Disease Screening Nat Reagent  
Market Forecast by Test*

*U.S.A., NAT Market by Major Supplier*

*U.S.A., HIV/Hepatitis C NAT Market Reagent Sales  
By Major Supplier*

*U.S.A., West Nile Virus NAT Market Reagent Sales  
By Major Supplier*